Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
colorectal cancer
Biotech
PDS halts ph. 3 cancer therapy to focus on colorectal contender
PDS Biotechnology has called time on its phase 3 head and neck cancer therapy to channel resources to a metastatic colorectal cancer drug in phase 2.
James Waldron
Aug 13, 2026 9:55am
Guardant taps Patrick Dempsey for colorectal cancer awareness
Jul 28, 2026 8:54am
FDA approves Freenome colorectal cancer blood test
Jul 27, 2026 10:29am
Agenus scraps ph. 3 colorectal study to narrow focus to colon
Jul 13, 2026 7:55am
Exelixis’ Cabometyx successor misses primary endpoint in CRC trial
Jun 22, 2026 3:40pm
ASCO: Cardiff posts updated colorectal data before pivotal push
Jun 2, 2026 9:06am
